Further work on HCC has demonstrated that methylation of TFPI-2 is linked to a high risk of advanced tumor stage, early tumor recurrence, poor prognosis, and that it could be a potential negative prognostic biomarker in patients with HCC after hepatectomy [106]. This evidence concerns the gene TFPI2 and neoplasm.